Cover of: The effect of disease states on drug pharmacokinetics | Read Online
Share

The effect of disease states on drug pharmacokinetics

  • 829 Want to read
  • ·
  • 44 Currently reading

Published by American Pharmaceutical Association, Academy of Pharmaceutical Sciences in Washington, D.C .
Written in English

Subjects:

  • Drug metabolism -- Congresses,
  • Drugs -- Physiological effect -- Congresses,
  • Pharmacology -- Congresses

Book details:

Edition Notes

StatementLeslie Z. Benet, editor.
ContributionsBenet, Leslie Z., 1937-, Academy of Pharmaceutical Sciences. Basic Pharmaceutics Section., American Pharmaceutical Association.
Classifications
LC ClassificationsRM21 E48 1976
The Physical Object
Paginationxiv, 252 p. :
Number of Pages252
ID Numbers
Open LibraryOL21951352M
ISBN 100917330110

Download The effect of disease states on drug pharmacokinetics

PDF EPUB FB2 MOBI RTF

The effect of disease on the serum protein binding of phenytoin and propranolol, model drugs for weak acids and bases, respectively, was studied in dogs. Our preliminary investigations showed that, as in humans, the binding of organic bases is increased in diseases Cited by: 1. Effect of Disease on Drug Metabolism The activity of several cytochrome P enzymes (eg, CYP1A2, CYP3A4, CYP2C19, CYP2C9) can be inhibited by disease states that are characterized by infection or inflammation. These disease states increase cytokine concentrations in response to infection, trauma, ischemia, immune-activated T cells, and toxins. Cytokines associated with this CYP inhibitor effect . Effect of Disease State on Drug Disposition. Drug responses are affected by disease states because of changes in both pharmacokinetics and pharmacodynamics. This is especially apparent with diseases that affect the processes of drug disposition and pharmacokinetics—absorption, protein binding, metabolism, and excretion (Yeung et al., ). The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the.

  Applications of pharmacokinetics parameters in disease states 1. Applications of Pharmacokinetics parameters in disease states Pathological factors influences drug responses1: Cardiovascular DiseasesPharmacokinetics in cardiac failureCardiac failure and its multiple organ effects have variable influences onpharmacokinetic processes. Pharmacodynamics, described as what a drug does to the body, involves receptor binding, postreceptor effects, and chemical interactions. Drug pharmacokinetics determines the onset, duration, and intensity of a drug’s effect. Formulas relating these processes summarize the pharmacokinetic behavior of most drugs (see table Formulas Defining. Introduction to Pharmacokinetics and Pharmacodynamics Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabo-lism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Disease States and Drug Pharmacokinetics. Jeffrey R. Koup PharmD. Corresponding Author. Department of Pharmacokinetics and Drug Metabolism, Parke‐Davis Pharmaceutical Research Division, Warner‐Lambert Company. Pharmacokinetics and Drug Metabolism, Parke‐Davis Pharmaceutical Research Division, Warner‐Lambert Company, Plymouth Rd Cited by: 8.

guide drug dosage adjustment in patients with hepatic dysfunction. Keywords cdysfunction. cokinetics Introduction The liver plays a central role in the absorption, distribution, and elimination kinetics of most drugs and many active or inactive drug metabolites. It is not only the most Cited by: Pharmacokinetics refers to the sum of the processes the body is con-ducting on the drug. In contrast, refers to the pharmacodynamics physiologic and biochemical effects of the drug on the body. The intended effects of the drug, at a concentration that minimizes poten-tial adverse effects, are determined by the intricate balance between PK and PD. However, for other drug classes and especially for other disease states, such as invasive aspergillosis, the optimal outcome measure in the animal model is unknown. In this case, it is not uncommon for experimental model PD studies to report PD targets for multiple outcome measures, such as net stasis, 1-log kill, and 50% maximal by: Information on drug absorption and disposition in infants and children has increased considerably over the past 2 decades. However, the impact of specific age-related effects on pharmacokinetics, pharmacodynamics, and dose requirements remains poorly understood. Absorption can be .